CCL2 and malignant glioma: Several studies have revealed that the macrophage chemoattractant protein-1 (MCP-1) (33) and hepatocyte growth factor (HGF) (34) are able to promote MSC migration into malignant gliomas, confirming the potential applications of genetically modified MSCs for cancer gene therapy.